NEW
YORK, Dec. 6, 2023 /PRNewswire/ -- Julie
& Holleman LLP, a nationally recognized shareholder rights law
firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics
Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. The firm has already
identified potential conflicts of interest related to the
merger.
For a free consultation and to learn about our investigation,
click here or visit: https://julieholleman.com/?p=3218
On December 6, 2023, Cerevel
announced that it had entered into an agreement for the company to
be acquired by AbbVie for $45 per
share, or a total of $8.7 billion.
The transaction, which is subject to shareholder approval, is
expected to close in mid-2024.
Julie & Holleman, whose attorneys have helped secure
hundreds of millions of dollars for shareholders, is concerned
about potential conflicts, including related to Cerevel's largest
shareholder, Bain Capital.
If you would like more information about our investigation,
please contact W. Scott Holleman at
scott@julieholleman.com or (917) 325-3798, or submit your
information by clicking here.
Julie & Holleman is a boutique law firm that focuses on
shareholder litigation, including derivative actions, mergers and
acquisitions cases, securities fraud class actions,
and corporate investigations. The firm's attorneys litigate in
state and federal courts across the nation and have helped secure
hundreds of millions of dollars for aggrieved companies and their
shareholders. For more information about the firm, please visit
https://www.julieholleman.com/. This notice may constitute attorney
advertising. Past results do not guarantee future outcomes.
CONTACT INFORMATION
Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cere-merger-announcement-julie--holleman-llp-announces-investigation-into-potential-claims-regarding-abbvies-proposed-acquisition-of-cerevel-therapeutics-302008308.html
SOURCE Julie & Holleman LLP
